The significance of the alteration of 8-OHdG in serous ovarian carcinoma

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Xu, Xia ^a   Wang, Yan ^b   Guo, Wenwen ^c   Zhou, Yiqing ^a   Lv, Chunmei ^a   Chen, Xiaoxiang ^a,d   Liu, Kaijiang ^e  

^a JIANGSU CANCER HOSPITAL   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^d SOUTHEAST UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

8 OHdG; Epithelial ovarian cancer; hOGG1 gene; p53; Serous carcinoma

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DNA; HOGG1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYSTADENOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; SEROUS OVARIAN CARCINOMA;

EID: 84886444035     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-74     Document Type: Article

References (39)

1. Cancer statistics. Jemal A, Siegel R, Xu J, et al. CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Estimates of cancer incidence in China for 2000 and projections for 2005. Yang L, Parkin DM, Ferlay J, et al. Cancer Epidemiol Biomarkers Prev 2005 14 243 250 15668501 (Pubitemid 40165308)
3. Profiling studies in ovarian cancer: a review. Fehrmann RS, Li XY, van der Zee AG, et al. Oncologist 2007 12 960 966 10.1634/theoncologist.12-8-960 17766655 (Pubitemid 47359138)
4. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. Wang F, Ye Y, Xu X, et al. J Ovarian Res 2013 6 14 10.1186/1757-2215-6-14 23402322
5. Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer. Xu X, Wang Y, Wang F, et al. J Ovarian Res 2013 6 31 10.1186/1757-2215-6-31 23618037
6. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Shih Ie M, Kurman RJ, Am J Pathol 2004 164 1511 1518 10.1016/S0002-9440(10)63708-X 15111296 (Pubitemid 38529752)
7. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Chen X, Zhang J, Zhang Z, et al. Hum Pathol 2013 44 2373 2384 10.1016/j.humpath.2013.05.001 23850493
8. My approach to and thoughts on the typing of ovarian carcinomas. McCluggage WG, J Clin Pathol 2008 61 152 163 17704261 (Pubitemid 351218874)
9. The DNA damage response: ten years after. Harper JW, Elledge SJ, Mol Cell 2007 28 739 745 10.1016/j.molcel.2007.11.015 18082599 (Pubitemid 350217064)
10. Screening for breast and ovarian cancer: the relevance of family history. Pharoah PD, Stratton JF, Mackay J, Br Med Bull 1998 54 823 838 10.1093/oxfordjournals.bmb.a011732 10367417 (Pubitemid 29000831)
11. DNA damage and repair: from molecular mechanisms to health implications. Altieri F, Grillo C, Maceroni M, et al. Antioxid Redox Signal 2008 10 891 937 10.1089/ars.2007.1830 18205545 (Pubitemid 351301368)
12. The mechanics of base excision repair, and its relationship to aging and disease. Wilson DM 3rd, Bohr VA, DNA Repair (Amst) 2007 6 544 559 10.1016/j.dnarep.2006.10.017 17112792 (Pubitemid 46357056)
13. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Tuhkanen H, Anttila M, Kosma VM, et al. Int J Cancer 2004 109 247 252 10.1002/ijc.11733 14750176 (Pubitemid 38240927)
14. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Manderson EN, Presneau N, Provencher D, et al. Mol Carcinog 2002 34 78 90 10.1002/mc.10051 12112314 (Pubitemid 34606510)
15. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p253 and TP53 mutations in ovarian cancer. Arcand SL, Provencher D, Mes-Masson AM, et al. Int J Oncol 2005 27 1315 1320 16211227
16. Estimating the effect of human base excision repair protein variants on the repair of oxidative DNA base damage. Sokhansanj BA, Wilson DM 3rd, Cancer Epidemiol Biomarkers Prev 2006 15 1000 1008 10.1158/1055-9965.EPI-05-0817 16702383 (Pubitemid 43823530)
17. Functional polymorphisms of the hOGG1 gene confer risk to type 2 epithelial ovarian cancer in Chinese. Chen X, Liu X, Wang J, et al. Int J Gynecol Cancer 2011 21 1407 1413 10.1097/IGC.0b013e31823122c6 21997177
18. Two functional variations in 5'-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese. Chen X, Wang J, Guo W, et al. Breast Cancer Res Treat 2011 127 795 803 10.1007/s10549-010-1284-2 21153698
19. Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women. Xie H, Xia K, Rong H, et al. Breast 2013 29 707 712
20. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Karihtala P, Soini Y, Vaskivuo L, et al. Int J Gynecol Cancer 2009 19 1047 1051 10.1111/IGC.0b013e3181ad0f0d 19820366
21. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Pylvas M, Puistola U, Kauppila S, et al. Eur J Cancer 2010 46 1661 1667 10.1016/j.ejca.2010.02.006 20206498
22. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. Ahmed AA, Etemadmoghadam D, Temple J, et al. J Pathol 2010 221 49 56 10.1002/path.2696 20229506
23. Association of base excision repair gene polymorphisms with ESRD risk in a Chinese population. Cai Z, Chen H, Tao J, et al. Oxid Med Cell Longev 2012 2012 928421 22720119
24. Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype. Karihtala P, Kauppila S, Puistola U, et al. Br J Cancer 2012 106 344 347 10.1038/bjc.2011.518 22108520
25. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Kurman RJ, Shih IM, Hum Pathol 2011 42 918 931 10.1016/j.humpath.2011.03.003 21683865
26. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, Shih IM, Am J Surg Pathol 2010 34 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
27. Oxidative DNA damage and 8-hydroxy-2-deoxyguanosine DNA glycosylase/apurinic lyase in human breast cancer. Li D, Zhang W, Zhu J, et al. Mol Carcinog 2001 31 214 223 10.1002/mc.1056 11536371 (Pubitemid 32831347)
28. Frequent allelic imbalance and loss of protein expression of the DNA repair gene hOGG1 in head and neck squamous cell carcinoma. Fan CY, Liu KL, Huang HY, et al. Lab Invest 2001 81 1429 1438 10.1038/labinvest.3780356 11598155 (Pubitemid 32980165)
29. Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Xie B, Freudenheim JL, Cummings SS, et al. Carcinogenesis 2006 27 307 310 10.1093/carcin/bgi215 16113052 (Pubitemid 43159884)
30. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Chan WY, Cheung KK, Schorge JO, et al. Am J Pathol 2000 156 409 417 10.1016/S0002-9440(10)64744-X 10666369 (Pubitemid 30643795)
31. Implication of p53 in base excision DNA repair: in vivo evidence. Seo YR, Fishel ML, Amundson S, et al. Oncogene 2002 21 731 737 10.1038/sj.onc.1205129 11850801 (Pubitemid 34146285)
32. Genetic variability in DNA repair proteins in age-related macular degeneration. Blasiak J, Synowiec E, Salminen A, et al. Int J Mol Sci 2012 13 13378 13397 10.3390/ijms131013378 23202958
33. Age-related loss of the DNA repair response following exposure to oxidative stress. Cabelof DC, Raffoul JJ, Ge Y, et al. J Gerontol A Biol Sci Med Sci 2006 61 427 434 10.1093/gerona/61.5.427 16720738 (Pubitemid 43794700)
34. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Vang R, Shih Ie M, Kurman RJ, Adv Anat Pathol 2009 16 267 282 10.1097/PAP. 0b013e3181b4fffa 19700937
35. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1). Noren Hooten N, Kompaniez K, Barnes J, et al. J Biol Chem 2011 286 44679 44690 10.1074/jbc.M111.255869 22057269
36. Investigational agents in development for the treatment of ovarian cancer. Westin SN, Herzog TJ, Coleman RL, Invest New Drugs 2013 31 213 229 10.1007/s10637-012-9837-3 22661305
37. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Audeh MW, Carmichael J, Penson RT, et al. Lancet 2010 376 245 251 10.1016/S0140-6736(10)60893-8 20609468
38. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Fong PC, Yap TA, Boss DS, et al. J Clin Oncol 2010 28 2512 2519 10.1200/JCO.2009.26.9589 20406929
39. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Gelmon KA, Tischkowitz M, Mackay H, et al. Lancet Oncol 2011 12 852 861 10.1016/S1470-2045(11)70214-5 21862407